Full-Time
Healthcare technology using AI for patient outcomes
No salary listed
Mid, Senior
Company Historically Provides H1B Sponsorship
Nashville, TN, USA
Frequent travel (> 50%) throughout the territory as needed.
Upload your resume to see how it matches 13 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to assist physicians in making informed treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Their business model involves charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive research capabilities.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
Illumina teams up with Tempus to expand DNA profiling beyond cancer.
Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.
Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO --(BUSINESS WIRE)--Mar. 11, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision
Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.
Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.